Patient-Representative Cell Line Models in a Heterogeneous Disease: Comparison of Signaling Transduction Pathway Activity Between Ovarian Cancer Cell Lines and Ovarian Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Dec 17

PMID 39682227

Authors

Cynthia S E Hendrikse

Pauline M M Theelen

Wim Verhaegh

Sandrina Lambrechts

Ruud L M Bekkers

Anja van de Stolpe

Jurgen M J Piek

Affiliations

Soon will be listed here.

Abstract

: Advances in treatment options have barely improved the prognosis of ovarian carcinoma (OC) in recent decades. The inherent heterogeneity of OC underlies challenges in treatment (development) and patient stratification. One hurdle for effective drug development is the lack of patient-representative disease models available for preclinical drug research. Based on quantitative measurement of signal transduction pathway (STP) activity in cell lines, we aimed to identify cell line models that better mirror the different clinical subtypes of OC. : The activity of seven oncogenic STPs (signal transduction pathways) was determined by previously described STP technology using transcriptome data from untreated OC cell lines available in the GEO database. Hierarchal clustering of cell lines was performed based on STP profiles. Associations between cell line histology (original tumor), cluster, and STP profiles were analyzed. Subsequently, STP profiles of clinical OC tissue samples were matched with OC cell lines. : Cell line search resulted in 80 cell line transcriptome data from 23 GEO datasets, with 51 unique cell lines. These cell lines were derived from eight different histological OC subtypes (as determined for the primary tumor). Clustering revealed seven clusters with unique STP profiles. When borderline tumors (n = 6), high-grade serous (n = 51) and low-grade (n = 31) OC were matched with cell lines, twelve different cell lines were identified as potentially patient-representative OC cell line models. : Based on STP activity, we identified twelve different cell lines that were the most representative of the common subtypes of OC. These findings are important to improve drug development for OC.

References

Zeller C, Dai W, Steele N, Siddiq A, Walley A, Wilhelm-Benartzi C . Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. DOI: 10.1038/onc.2011.611. View

Srinivasan S, Su M, Ravishankar S, Moore J, Head P, Dixon J . TLR-exosomes exhibit distinct kinetics and effector function. Sci Rep. 2017; 7:41623. PMC: 5349571. DOI: 10.1038/srep41623. View

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

You M, Xie Z, Zhang N, Zhang Y, Xiao D, Liu S . Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1):196. PMC: 10172373. DOI: 10.1038/s41392-023-01442-3. View

van Lieshout L, van der Ploeg P, Wesseling-Rozendaal Y, van de Stolpe A, Bosch S, Lentjes-Beer M . Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma. Cancers (Basel). 2021; 13(20). PMC: 8533979. DOI: 10.3390/cancers13205101. View

van de Stolpe A, Holtzer L, van Ooijen H, Inda M, Verhaegh W . Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types. Sci Rep. 2019; 9(1):1603. PMC: 6367506. DOI: 10.1038/s41598-018-38179-x. View

Mirabelli P, Coppola L, Salvatore M . Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers (Basel). 2019; 11(8). PMC: 6721418. DOI: 10.3390/cancers11081098. View

Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha J, Ahmad S . Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019; 8(16):7018-7031. PMC: 6853829. DOI: 10.1002/cam4.2560. View

Nair A, Chauhan P, Saha B, Kubatzky K . Conceptual Evolution of Cell Signaling. Int J Mol Sci. 2019; 20(13). PMC: 6651758. DOI: 10.3390/ijms20133292. View

10.

Lahtinen A, Lavikka K, Virtanen A, Li Y, Jamalzadeh S, Skorda A . Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma. Cancer Cell. 2023; 41(6):1103-1117.e12. DOI: 10.1016/j.ccell.2023.04.017. View

11.

Ingemarsdotter C, Tookman L, Browne A, Pirlo K, Cutts R, Chelela C . Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol. 2015; 9(4):791-805. PMC: 5528770. DOI: 10.1016/j.molonc.2014.12.007. View

12.

Holtzer L, Wesseling-Rozendaal Y, Verhaegh W, van de Stolpe A . Measurement of activity of developmental signal transduction pathways to quantify stem cell pluripotency and phenotypically characterize differentiated cells. Stem Cell Res. 2022; 61:102748. DOI: 10.1016/j.scr.2022.102748. View

13.

Massard C, Michiels S, Ferte C, Le Deley M, Lacroix L, Hollebecque A . High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov. 2017; 7(6):586-595. DOI: 10.1158/2159-8290.CD-16-1396. View

14.

van de Stolpe A, Verhaegh W, Blay J, Ma C, Pauwels P, Pegram M . RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. Front Genet. 2021; 11:598118. PMC: 7893109. DOI: 10.3389/fgene.2020.598118. View

15.

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

16.

Spillman M, Manning N, Dye W, Sartorius C, Post M, Harrell J . Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis. Cancer Res. 2010; 70(21):8927-36. PMC: 3804411. DOI: 10.1158/0008-5472.CAN-10-1238. View

17.

Tothill R, Tinker A, George J, Brown R, Fox S, Lade S . Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16):5198-208. DOI: 10.1158/1078-0432.CCR-08-0196. View

18.

Kulbe H, Chakravarty P, Leinster D, Charles K, Kwong J, Thompson R . A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2011; 72(1):66-75. PMC: 3252703. DOI: 10.1158/0008-5472.CAN-11-2178. View

19.

Tan T, Miow Q, Huang R, Wong M, Ye J, Lau J . Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med. 2013; 5(7):1051-66. PMC: 3721473. DOI: 10.1002/emmm.201201823. View

20.

C Mok S, Bonome T, Vathipadiekal V, Bell A, Johnson M, Wong K . A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009; 16(6):521-32. PMC: 3008560. DOI: 10.1016/j.ccr.2009.10.018. View